STABLE AAV PRODUCER CELL LINES

CEVEC’s ELEVECTA® technology takes viral vector manufacturing to the next level.

Through a unique producer cell line approach, ELEVECTA® enables high-performance AAV vector production delivering consistent quality in all types and formats of suspension bioreactors up to large scale production. No need for helper viruses, expensive transfection reagents or cGMP-grade plasmids. Just propagate your producer cells and switch on production.

Start producing AAV.

From day one in a robust, reliable and fully scalable format.

ELEVECTA®
PREMIUM TECHNOLOGY
FOR PREMIUM THERAPIES

STABLE
PRODUCER CELLS

All components for AAV production stably integrated into one producer cell line

FULL
SCALABILITY

Scaling up from shake flask to large scale bioreactor without drop in productivity

CONSISTENT
QUALITY

Consistent AAV quality across batches – no transfection steps

ROBUST
PROCESS

Reliable AAV production in suspension bioreactors and serum-free media

ELEVECTA® PACKAGES

Designed to your specific needs, CEVEC offers three different ELEVECTA® packages.

ELEVECTA®
STARTER PACKAGE

The ELEVECTA® Starter Package is the ideal starting point for fast supply of AAV vector material for pre-clinical research and early clinical stages. The Starter Package is compatible with all common serotypes and any proprietary, engineered capsids. Service is available at various scales and formats. As the Starter Package is based on the ELEVECTA® Alpha Cell Line, you can easily upgrade to the ELEVECTA® Product Package. Use the same platform for all clinical programs and up to commercial manufacturing. Never switch your AAV production system again.

ELEVECTA®
PRODUCT PACKAGE

The ELEVECTA® Product Package is specifically designed to provide a customized service package from gene sequence to GMP production. The package includes all components you need for manufacturing your dedicated individual AAV gene therapy vector. Starting with your specific vector concept, we design and develop a producer cell line and provide you, if requested, with a fully tested MCB, a complete process package and all regulatory documentation. Compatible with all common serotypes and any proprietary, engineered capsids. Get full control over your AAV manufacturing process with your custom-made ELEVECTA® Producer Cell Line.

ELEVECTA®
PARTNER PACKAGE

Specific for Pharma and Biotech companies with a larger portfolio of gene therapy programs, CEVEC offers the ELEVECTA® Partner Package. Enables partners to make use of the ELEVECTA® production technology across their entire AAV-based gene therapy programs. Besides a license to the ELEVECTA® technology platform, CEVEC offers cell line development services, technical training modules and regulatory documentation as needed. Become an ELEVECTA® Partner and benefit from a preferred and flexible access to the full potential of the ELEVECTA® technology for all your AAV programs.

PACKAGE DETAILS

ELEVECTA®
STARTER PACKAGE
ELEVECTA®
PRODUCT PACKAGE
ELEVECTA®
PARTNER PACKAGE
BEST SUITED FORPharma & Biotech with gene therapy programs in early stage
Pharma & Biotech with specific gene therapy program Pharma with portfolio of gene therapy programs
DEVELOPMENT STAGEResearch / Pre-clinical Pre-clinical / Early clinical Any development stage
APPLICABLE SCALESLab scaleLab scale to commercial scaleLab scale to commercial scale
SERVICES INCLUDED

  • Fast access to AAV research material while vector design is being finalized
  • Process development support
  • Analytical support

  • Producer Cell Line development for specific program
  • Process development support
  • Analytical support
  • GMP MCB/WCB, including release testing
  • Regulatory documentation

  • Producer Cell Line Development for multiple programs
  • Process development support
  • Analytical support
  • GMP MCB/WCB, including release testing
  • Regulatory documentation
  • Technology transfer & training modules

USE OF PRODUCTSResearch useClinical development and commercializationClinical development and commercialization
LICENSEIndividual gene therapy programMultiple gene therapy programs
© CEVEC Pharmaceuticals GmbH 2020